

SEARCH REQUEST FORM

Access DB# 80199

Scientific and Technical Information Center

Requester's Full Name:

Art Unit: 1625Examiner #: 78264 Date: 11/11/02
Phone Number 30 605 1153 Serial Number: 09 659 643Mail Box and Bldg/Room Location: 3 DO1-4006

Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Joe Bib's CopyInventors (please provide full names): Joe Bib

Point of Contact:

Beverly Shears

Technical Info. Specialist

CM1 1E05 Tel: 308-4994

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Earliest Priority Filing Date: _____

Please search for Compound
of formula I and its uses
as an anti-tumor and
in processes for treating
oral tumors in mammals
together with a response modifier
and a non-thymidine agent
as described in claim 1.
11/10/02

RECEIVED
NOV 15 2002
STANISLAW

STAFF USE ONLY

Searcher: Beverly e4994

Searcher Phone #:

Searcher Location:

Date Searcher Picked Up:

Date Completed: 11-18-02

Searcher Prep & Review Time:

Clerical Prep Time:

Online Time:

Type of Search

Vendors and cost where applicable

NA Sequence (#)

STN

AA Sequence (#)

Dialog

Structure (#)

Questel/Orbit

Bibliographic

Dr. Link

Litigation

Lexis/Nexis

Fulltext

Sequence Systems

Patent Family

WWW/Internet


Other

Other (specify)

Reyes, H.
09/659643

09/659643

L1 ((FILE=REGISTRY) ENTERED AT 15:08:46 ON 18 NOV 2002)
STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L2 (106) SEA FILE=REGISTRY SSS FUL L1

L3 STR



R₁ = H

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15


STEREO ATTRIBUTES: NONE

L4 ((SEA FILE=REGISTRY SUB=L2 SSS FUL L3)

100.0% PROCESSED 103 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L5 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

09/659643

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2002127198 A1 20020912 US 2001-792480 20010223
PRIORITY APPLN. INFO.: US 2001-792480 A 20010223
US 1999-150510P P 19990824
US 2000-648400 A2 20000824

OTHER SOURCE(S): MARPAT 137:222033

AB Compns. and methods for enhancing delivery of drugs, diagnostic and other agents across epithelial tissues, including into and across ocular tissues and blood-brain barrier are provided. The compns. and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino side chain moieties to enhance delivery of a compd. conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compd. The delivery-enhancing polymers include, for example, poly-arginine mols. that are preferably between about 6 and 25 residues in length. For example, a series of structural characteristics including sequence length, amino acid compn., and chirality that influence the ability of Tat49-57 to enter cells is identified. These characteristics provided the blueprint for the design of a series of novel peptoids, of which 17 members were synthesized and assayed for cellular uptake. This research established that the peptide backbone and hydrogen bonding along that backbone are not required for cellular uptake, that the guanidino head group is superior to other cationic subunits, and most significantly, that an extension of the alkyl chain between the backbone and the head group provides superior transporters. In addn. to better uptake performance, these novel peptoids offer several advantages over Tat49-57 including cost-effectiveness, ease of synthesis of analogs, and protease stability. These features along with their significant water solv. (>100 mg/mL) indicate that these novel peptoids could serve as effective transporters for the mol. delivery of drugs, drug candidates, and other agents into cells.

IT 455282-37-8P 455282-38-9P 455282-39-0P
455282-40-3P 455282-41-4P 455282-42-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(drug conjugates with peptide transporter contg. amidino or
guanidino moieties for enhanced delivery across epithelium)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN
THE RE FORMAT

L10 ANSWER 2 OF 5 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:265375 HCPLUS

DOCUMENT NUMBER: 134:311431

TITLE: Preparation of novel amino acid-related carbamates and ureas

INVENTOR(S): Rana, Tariq M.; Hwang, Seongwoo; Tamilarasu,
Natarajan

PATENT ASSIGNEE(S): University of Medicine and Dentistry of New

09/659643

SOURCE: Jersey, USA
PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025188	A1	20010412	WO 2000-US27398	20001004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6420591	B1	20020716	US 2000-679728	20001004
EP 1226115	A1	20020731	EP 2000-968691	20001004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			US 1999-157646P	P 19991004
			WO 2000-US27398	W 20001004

mb.
pm
gal

OTHER SOURCE(S): MARPAT 134:311431

AB Novel carbamates and ureas H-Y-Y-Y-NH₂ [each Y is independently a radical NHC*H[(CH₂)_mR₁]CO, N[(CH₂)_mR₁]CH₂CO, or NHC*H[(CH₂)_mR₁]CH₂O₂C (Q), where each R₁ is independently selected from -NH₂, -NHC(:NH)NH₂, and -CH₂C(:NH)NH₂; each m is independently an integer 3-7; each * is an (R) or (S) chiral center; and with the proviso that at least one Y is a radical having the structure of Q] and their pharmaceutically acceptable salts were prep'd. for treating or preventing cancer, inflammation, or a viral infection. Thus, H₂NCONHCH[(CH₂)₃NHC(:NH)NH₂]CH₂NHCONHCH[(CH₂)₄NH₂]CH₂NH₂, with the chirality of arginine and lysine, was prep'd. and showed Ki = 50 nM for binding to HIV TAR RNA.

IT 334000-12-3P 334000-13-4P 334000-14-5P
334000-15-6P 334000-16-7P 334000-17-8P
334000-18-9P 334000-19-0P 334000-20-3P
334000-21-4P 334000-22-5P 334000-23-6P
334000-24-7P 334000-25-8P 334000-26-9P
334000-27-0P 334000-28-1P 334000-29-2P
334000-64-5P 334000-65-6P 334000-66-7P
334000-67-8P 334000-68-9P 334000-69-0P
334000-70-3P 334000-71-4P 334000-72-5P
334000-73-6P 334000-74-7P 334000-75-8P
334000-76-9P 334000-77-0P 334000-78-1P
334000-79-2P 334000-80-5P 334000-81-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prep'n. of amino acid-related carbamates and ureas)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN

09/659643

THE RE FORMAT

L10 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:208131 HCAPLUS
DOCUMENT NUMBER: 134:231861
TITLE: Method of potentiating chemotherapy and treating solid tumors
INVENTOR(S): Gibbons, James Joseph, Jr.; Dukart, Gary; Lucas, Judy; Speicher, Lisa Anne
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019399	A2	20010322	WO 2000-US25008	20000912
WO 2001019399	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014001	A	20020521	BR 2000-14001	20000912
EP 1214092	A2	20020619	EP 2000-961841	20000912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			US 1999-396051 A 19990915	
			WO 2000-US25008 W 20000912	

OTHER SOURCE(S): MARPAT 134:231861

AB This invention provides a method of treating solid tumors which comprises administering an effective amt. of a combination of (1) a bioresponse modifier and (2) a chemotherapeutic agent. This invention also provides a method of potentiating the effects of a chemotherapeutic regimen in a mammal in need of treatment with such regimen which comprises administering a bioresponse modifier in addn. to a chemotherapeutic regimen. The potentiating effect of the bioresponse modifier [R-(R*, R*)]-N-[R-6-carboxy-N2-[(2-carboxy-1-methyl-2-[(1-oxoheptyl)amino]ethoxy]carbonyl]-L-lysyl]alanine and paclitaxel was demonstrated in mice.

IT 160705-84-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potentiating chemotherapy and treating solid tumors)

L10 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:152863 HCAPLUS
DOCUMENT NUMBER: 134:204756
TITLE: Methods for the detection, analysis and

*Save
Appr
Save
GJB*

09/659643

INVENTOR(S): isolation of nascent proteins
Rothschild, Kenneth J.; Gite, Sadanand; Olejnik,
Jerzy
PATENT ASSIGNEE(S): Ambergen, Inc., USA
SOURCE: PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014578	A1	20010301	WO 2000-US23233	20000823
W: AE, AG, AL, AM, AT, AU, AZ, CN, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LR, LS, LT, LU, LV, MA, MD, PL, PT, RO, RU, SD, SE, SG, UA, UG, US, UZ, VN, YU, ZA, BA, BB, BG, BR, BY, BZ, CA, CH, EE, ES, FI, GB, GD, GE, GH, KG, KP, KR, KZ, LC, LK, MG, MK, MN, MW, MX, MZ, NO, NZ, TJ, TM, TR, TT, TZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6303337	B1	20011016	US 1999-382950	19990825
US 6306628	B1	20011023	US 1999-382736	19990825
EP 1210449	A1	20020605	EP 2000-957758	20000823
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 2002132248	A1	20020919	US 2001-973145	20011009
PRIORITY APPLN. INFO.:			US 1999-382736	A 19990825
			US 1999-382950	A 19990825
			WO 2000-US23233	W 20000823

AB This invention relates to non-radioactive markers that facilitate the detection and anal. of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins contg. these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems assocd. with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes.

IT 328387-26-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(methods for detection, anal. and isolation of nascent proteins)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 5 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:324507 HCPLUS
DOCUMENT NUMBER: 122:106538
TITLE: Preparation of peptide urethane and urea derivatives that induce cytokine production
INVENTOR(S): Ayral-Kaloustian, Semiramis; Schow, Steven R.; Du, Mila T.; Gibbons, James J., Jr.
PATENT ASSIGNEE(S): American Cyanamid Co., USA
SOURCE: U.S., 25 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent

to check

09/659643

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5312831	A	19940517	US 1993-63174	19930512
US 5545662	A	19960813	US 1994-213303	19940314
EP 652228	A1	19950510	EP 1994-106123	19940420
EP 652228	B1	19961023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 144533	E	19961115	AT 1994-106123	19940420
ES 2094004	T3	19970101	ES 1994-106123	19940420
CZ 290445	B6	20020717	CZ 1994-981	19940422
SK 281120	B6	20001211	SK 1994-491	19940428
HU 67038	A2	19950130	HU 1994-1444	19940506
HU 219768	B	20010730		
JP 07179414	A2	19950718	JP 1994-119532	19940509
IL 109602	A1	20000601	IL 1994-109602	19940509
CA 2123261	AA	19941113	CA 1994-2123261	19940510
FI 9402186	A	19941113	FI 1994-2186	19940511
NO 9401786	A	19941114	NO 1994-1786	19940511
AU 9463043	A1	19941117	AU 1994-63043	19940511
AU 669064	B2	19960523		
ZA 9403266	A	19950112	ZA 1994-3266	19940511
RU 2135515	C1	19990827	RU 1994-16389	19940511
PL 179984	B1	20001130	PL 1994-303396	19940511
CN 1100413	A	19950322	CN 1994-105671	19940512
TW 380129	B	20000121	TW 1994-83107431	19940813
US 5602275	A	19970211	US 1995-449878	19950525
US 5616612	A	19970401	US 1995-451099	19950525
US 5633280	A	19970527	US 1995-451085	19950525
US 5658945	A	19970819	US 1995-449968	19950525

PRIORITY APPLN. INFO.: US 1993-63174 A3 19930512
US 1994-213303 A3 19940314

OTHER SOURCE(S): MARPAT 122:106538
GI



AB Title compds. [I; R₁, R₃, R_a = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, vinyl, acetylene, amino, acylamino, aryl, aralkyl, aryloxy, heterocycl, etc.; R₂, R_b, R_c = (protected) carboxy, carboxylalkyl, carboxamide; X = O, S; R₄ = H, protecting group], were prep'd. Thus, [R-(R^{*},R^{*})]-N-(R)-6-carboxy-N2-[2-carboxy-1-

09/659643

methyl-2-[(1-oxoheptyl)amino]ethoxy]carbonyl]lysyl-D-alanine (soln. phase prepns. given) at 0.1 mg/kg s.c. in mice induced 4802 U/mL of IL-6. It may be useful in the treatment of **cancer**, AIDS, aplastic anemia, myelodysplastic syndrome, infectious disease, and in the enhancement of immune response.

IT 160578-69-8P 160578-70-1P 160578-71-2P
160578-72-3P 160578-73-4P 160579-15-7P
160579-16-8P 160579-17-9P 160579-18-0P
160705-77-1P 160705-78-2P 160705-79-3P
160705-81-7P 160705-82-8P 160705-83-9P
160705-84-0P 160705-85-1P 160705-86-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepns. of, for induction of cytokine prodn.)

FILE 'REGISTRY' ENTERED AT 15:17:51 ON 18 NOV 2002

L11 61 SEA FILE=REGISTRY ABB=ON PLU=ON (160705-84-0/BI OR
160578-69-8/BI OR 160578-70-1/BI OR 160578-71-2/BI OR
160578-72-3/BI OR 160578-73-4/BI OR 160579-15-7/BI OR
160579-16-8/BI OR 160579-17-9/BI OR 160579-18-0/BI OR
160705-77-1/BI OR 160705-78-2/BI OR 160705-79-3/BI OR
160705-81-7/BI OR 160705-82-8/BI OR 160705-83-9/BI OR
160705-85-1/BI OR 160705-86-2/BI OR 328387-26-4/BI OR
334000-12-3/BI OR 334000-13-4/BI OR 334000-14-5/BI OR
334000-15-6/BI OR 334000-16-7/BI OR 334000-17-8/BI OR
334000-18-9/BI OR 334000-19-0/BI OR 334000-20-3/BI OR
334000-21-4/BI OR 334000-22-5/BI OR 334000-23-6/BI OR
334000-24-7/BI OR 334000-25-8/BI OR 334000-26-9/BI OR
334000-27-0/BI OR 334000-28-1/BI OR 334000-29-2/BI OR
334000-64-5/BI OR 334000-65-6/BI OR 334000-66-7/BI OR
334000-67-8/BI OR 334000-68-9/BI OR 334000-69-0/BI OR
334000-70-3/BI OR 334000-71-4/BI OR 334000-72-5/BI OR
334000-73-6/BI OR 334000-74-7/BI OR 334000-75-8/BI OR
334000-76-9/BI OR 334000-77-0/BI OR 334000-78-1/BI OR
334000-79-2/BI OR 334000-80-5/BI OR 334000-81-6/BI OR
455282-37-8/BI OR 455282-38-9/BI OR 455282-39-0/BI OR
455282-40-3/BI OR 455282-41-4/BI OR 455282-42-5/BI)

=> d 1,7,43,44,53,57 ide can


L11 ANSWER 1 OF 61 REGISTRY COPYRIGHT 2002 ACS
RN 455282-42-5 REGISTRY
CN L-Lysinamide, D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-N6-[2-[(1R,2S)-2-(benzoylamino)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetoxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-phenylethoxy]-2-oxoethyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C108 H172 N40 O25
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK


Absolute stereochemistry.

09/659643

PAGE 1-A




PAGE 1-B




09/659643

PAGE 2-A



PAGE 3-A




1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:222033

L11 ANSWER 7 OF 61 REGISTRY COPYRIGHT 2002 ACS
RN 334000-81-6 REGISTRY
CN 5,10-Dioxa-2,7-diazaundecanoic acid, 11-amino-3,8-bis(4-aminobutyl)-
6,11-dioxo-, (2R)-2,5-diamino-5-oxopentyl ester, (3S,8S)- (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C20 H41 N7 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

09/659643



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 134:311431

L11 ANSWER 43 OF 61 REGISTRY COPYRIGHT 2002 ACS
RN 328387-26-4 REGISTRY
CN 10-Oxa-2,8,13,20-tetraazapentacosanoic acid, 3-carboxy-25-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-11-(2-nitrophenyl)-9,14,21-trioxo-, 1-(9H-fluoren-9-ylmethyl) ester, (3S)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C46 H57 N7 O11 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:204756

L11 ANSWER 44 OF 61 REGISTRY COPYRIGHT 2002 ACS
 RN 160705-86-2 REGISTRY
 CN D-Alanine, N-[(R)-N2,6-dicarboxy-L-lysyl]-, N2-ester with
 N-[(4-butoxyphenyl)acetyl]-D-allothreonine (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H40 N4 O11
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)


09/659643

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 122:106538

L11 ANSWER 53 OF 61 REGISTRY COPYRIGHT 2002 ACS
RN 160579-18-0 REGISTRY
CN D-Allothreonine, N-[(4-butylphenyl)acetyl]-, phenylmethyl ester,
[1-[[[1-methyl-2-oxo-2-(phenylmethoxy)ethyl]amino]carbonyl]-6-oxo-6-
(phenylmethoxy)-5-[[[phenylmethoxy]carbonyl]amino]hexyl]carbamate
(ester), [1S-[1R*(S*),5S*]]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C56 H64 N4 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 122:106538

L11 ANSWER 57 OF 61 REGISTRY COPYRIGHT 2002 ACS
RN 160578-73-4 REGISTRY
CN D-Alanine, N-[(R)-6-carboxy-N2-[[1-[carboxy[(1-
oxoheptyl)amino]methyl]propoxy]carbonyl]-L-lysyl]-, [R-(R*,R*)]-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H40 N4 O10
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

09/659643



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 122:106538

FILE 'CAOLD' ENTERED AT 15:19:00 ON 18 NOV 2002
L12 U S L11

FILE 'USPATFULL' ENTERED AT 15:19:05 ON 18 NOV 2002
L13 10 S L11

L13 ANSWER 1 OF 10 USPATFULL

ACCESSION NUMBER: 2002:243062 USPATFULL
TITLE: N-terminal and C-terminal markers in nascent proteins
INVENTOR(S): Rothschild, Kenneth J., Newton, MA, UNITED STATES
Gite, Sadanand, Cambridge, MA, UNITED STATES
Olejnik, Jerzy, Brookline, MA, UNITED STATES
PATENT ASSIGNEE(S): AmberGen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132248	A1	20020919
APPLICATION INFO.:	US 2001-973145	A1	20011009 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-382950, filed on 25 Aug 1999, GRANTED, Pat. No. US 6303337		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105		
NUMBER OF CLAIMS:	48		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	36 Drawing Page(s)		
LINE COUNT:	4518		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected,		

09/659643

isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Methods are described for incorporating N-terminal, C-terminal and (optionally) affinity markers into a nascent protein

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 10 USPATFULL

ACCESSION NUMBER: 2002:235015 USPATFULL
TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues
INVENTOR(S): Rothbard, Jonathan B., Cupertino, CA, UNITED STATES
Wender, Paul A., Menlo Park, CA, UNITED STATES
McGrane, P. Leo, Mountain View, CA, UNITED STATES
Sista, Lalitha V.S., Sunnyvale, CA, UNITED STATES
Kirschberg, Thorsten A., Mountain View, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127198	A1	20020912
APPLICATION INFO.:	US 2001-792480	A1	20010223 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-648400, filed on 24 Aug 2000, PENDING		

*note! prior
Appl*

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-150510P	19990824 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	4029	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 10 USPATFULL

ACCESSION NUMBER: 2001:185067 USPATFULL
TITLE: Methods for the detection, analysis and isolation of Nascent proteins

09/659643

INVENTOR(S): Rothschild, Kenneth J., Newton, MA, United States
Gite, Sadanand, Cambridge, MA, United States
Olejnik, Jerzy, Allston, MA, United States
PATENT ASSIGNEE(S): Ambergen, Incorporated, Boston, MA, United States
(U.S. corporation)

NUMBER	KIND	DATE
US 6306628	B1	20011023
US 1999-382736		19990825 (9)

PATENT INFORMATION:
APPLICATION INFO.:
DOCUMENT TYPE:
FILE SEGMENT:
PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS:
LINE COUNT:

Schwartzman, Robert A.
Davis, Katharine F
Medlen & Carroll, LLP
26
1
38 Drawing Figure(s); 35 Drawing Page(s)
4586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 10 USPATFULL
ACCESSION NUMBER: 2001:178841 USPATFULL
TITLE: N-terminal and C-terminal markers in nascent proteins
INVENTOR(S): Rothschild, Kenneth J., Newton, MA, United States
Gite, Sadanand, Cambridge, MA, United States
Olejnik, Jerzy, Allston, MA, United States
PATENT ASSIGNEE(S): Amber Gen. Inc., Boston, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6303337	B1	20011016
US 1999-382950		19990825 (9)

PATENT INFORMATION:
APPLICATION INFO.:
DOCUMENT TYPE:
FILE SEGMENT:
PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS:
LINE COUNT:

Schwartzman, Robert A.
Davis, Katharine F
Medlen & Carroll, LLP
26
1
38 Drawing Figure(s); 35 Drawing Page(s)
4586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins

09/659643

containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Methods are described for incorporating N-terminal, C-terminal and (optionally) affinity markers into a nascent protein

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 10 USPATFULL

ACCESSION NUMBER: 97:73652 USPATFULL

TITLE: Urethanes and ureas that induce cytokine production

INVENTOR(S): Ayral-Kaloustian, Semiramis, Tarrytown, NY,
United States
Schow, Steven R., Washingtonville, NY, United States
Du, Mila T., Suffern, NY, United States
Gibbons, Jr., James J., Westwood, NY, United States

PATENT ASSIGNEE(S): American Cyanamid Company, Madison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658945		19970819
APPLICATION INFO.:	US 1995-449968		19950525 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-213303, filed on 14 Mar 1994, now patented, Pat. No. US 5545662 which is a division of Ser. No. US 1993-63174, filed on 12 May 1993, now patented, Pat. No. US 5312831		

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Goldberg, Jerome D.

LEGAL REPRESENTATIVE: Milowsky, Arnold S.

NUMBER OF CLAIMS: 3

EXEMPLARY CLAIM: 1

LINE COUNT: 1954

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 10 USPATFULL

ACCESSION NUMBER: 97:45042 USPATFULL

TITLE: Urethanes and ureas that induce cytokine production

INVENTOR(S): Ayral-Kaloustian, Semiramis, Tarrytown, NY,
United States
Schow, Steven R., Washingtonville, NY, United States
Du, Mila T., Suffern, NY, United States

09/659643

Gibbons, Jr., James J., Westwood, NJ, United States
PATENT ASSIGNEE(S): American Cyanamid Company, Madison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633280		19970527
APPLICATION INFO.:	US 1995-451085		19950525 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-213303, filed on 14 Mar 1994, now patented, Pat. No. US 5545662 which is a division of Ser. No. US 1993-63174, filed on 12 May 1993, now patented, Pat. No. US 5312831		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Milowsky, Arnold S.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1961		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 10 USPATFULL
ACCESSION NUMBER: 97:27199 USPATFULL
TITLE: Urethanes and ureas that enhance the growth of bone marrow progenitor cells
INVENTOR(S): Ayral-Kaloustian, Semiramis, Tarrytown, NY, United States
Schow, Steven R., Washingtonville, NY, United States
Du, Mila T., Suffern, NY, United States
Gibbons, Jr., James J., Westwood, NJ, United States
PATENT ASSIGNEE(S): American Cyanamid Company, Madison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616612		19970401
APPLICATION INFO.:	US 1995-451099		19950525 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-213303, filed on 14 Mar 1994, now patented, Pat. No. US 5545662 which is a division of Ser. No. US 1993-63174, filed on 12 Sep 1993, now patented, Pat. No. US 5312831		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cook, Rebecca		
LEGAL REPRESENTATIVE:	Milowsky, Arnold S.		

09/659643

NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 1956

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 10 USPATFULL

ACCESSION NUMBER: 97:12611 USPATFULL
TITLE: Urethanes and ureas that induce cytokine production
INVENTOR(S): Ayral-Kaloustian, Semiramis, Tarrytown, NY,
United States
Schow, Steven R., Washingtonville, NY, United States
Du, Mila T., Suffern, NY, United States
Gibbons, Jr., James J., Westwood, NJ, United States
PATENT ASSIGNEE(S): American Cyanamid Company, Madison, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5602275		19970211
US 1995-449878		19950525 (8)
Division of Ser. No. US 1994-213303, filed on 14 Mar 1994, now patented, Pat. No. US 5545662 which is a division of Ser. No. US 1993-63174, filed on 12 May 1993, now patented, Pat. No. US 5312831		

51 C

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shippen, Michael L.
LEGAL REPRESENTATIVE: Milowsky, Arnold S.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 1920

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 10 USPATFULL
ACCESSION NUMBER: 96:72910 USPATFULL

Searcher : Shears 308-4994

09/659643

TITLE: Urethanes and ureas that induce cytokine production
INVENTOR(S): Ayral-Kaloustian, Semiramis, Tarrytown, NY,
United States
Schow, Steven R., Washingtonville, NY, United
States
Du, Mila T., Suffern, NY, United States
Gibbons, Jr., James J., Westwood, NJ, United
States
PATENT ASSIGNEE(S): American Cyanamid Company, Madison, NJ, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5545662		19960813
APPLICATION INFO.:	US 1994-213303		19940314 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-63174, filed on 12 May 1993, now patented, Pat. No. US 5312831		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Milowsky, Arnold S.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1976		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel ureas and urethanes of Formula I:
##STR1## which stimulate cytokine production and may be used to
accelerate recovery from neutropenia accompanying radio- or
chemotherapy, bone marrow transplantation, or infections.
Compounds in the invention or pharmaceutical compositions
employing these compounds may be useful in the treatment of
cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and
infectious diseases, and in the enhancement of immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 10 USPATFULL
ACCESSION NUMBER: 94:42359 USPATFULL
TITLE: Urethanes and ureas that induce cytokine production
INVENTOR(S): Ayral-Kaloustian, Semiramis, Tarrytown, NY,
United States
Schow, Steven R., Washingtonville, NY, United
States
Du, Mila T., Suffern, NY, United States
Gibbons, Jr., James J., Westwood, NJ, United
States
PATENT ASSIGNEE(S): American Cyanamid Company, Wayne, NJ, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5312831		19940517
APPLICATION INFO.:	US 1993-63174		19930512 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shippen, Michael L.		

Searcher : Shears 308-4994

09/659643

LEGAL REPRESENTATIVE: Dow, K. J.

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

LINE COUNT: 1983

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'REGISTRY' ENTERED AT 15:19:25 ON 18 NOV 2002
L14 0 S ?"CARBONYL-L-LYSYL]-ALANINE"?/CNS

- Named compd
claim 5

FILE 'HCAPLUS' ENTERED AT 15:22:51 ON 18 NOV 2002
L15 301 S (ALANINE OR ALA) (S)LYSYL
L16 2 S L15(S) (OXOHEPTYL? OR OXO HEPTYL?)
L17 0 S L16 NOT L10

FILE 'MEDLINE,-BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO, CANCERLIT' ENTERED AT 15:23:40 ON 18 NOV 2002
L18 1 S L16

L18 ANSWER 1 OF 1 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2001-257851 [26] WPIDS
DOC. NO. CPI: C2001-077696
TITLE: Product for the treatment of solid tumors, e.g.
non-small cell lung carcinoma, glioma, ovarian
cancer, breast cancer, and prostate cancer,
comprises a bioresponse modifier and a
chemotherapeutic agent.
DERWENT CLASS: B05
INVENTOR(S): DUKART, G; GIBBONS, J J; LUCAS, J; SPEICHER, L A
PATENT ASSIGNEE(S): (AMHP) AMERICAN HOME PROD CORP; (AMHP) WYETH
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG
WO 2001019399	A2 20010322 (200126)*	EN	23	
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW			
AU 2000073736	A 20010417 (200140)			
BR 2000014001	A 20020521 (200238)			
EP 1214092	A2 20020619 (200240)	EN		
R:	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI			

09/659643

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001019399	A2	WO 2000-US25008	20000912
AU 2000073736	A	AU 2000-73736	20000912
BR 2000014001	A	BR 2000-14001	20000912
		WO 2000-US25008	20000912
EP 1214092	A2	EP 2000-961841	20000912
		WO 2000-US25008	20000912

FILING DETAILS:

PATENT NO	KIND	PATENT NO	
AU 2000073736	A	Based on	WO 200119399
BR 2000014001	A	Based on	WO 200119399
EP 1214092	A2	Based on	WO 200119399

PRIORITY APPLN. INFO: US 1999-396051 19990915

AN 2001-257851 [26] WPIDS

AB WO 200119399 A UPAB: 20010515

NOVELTY - Product (I) comprises a bioresponse modifier (BM) and a chemotherapeutic agent (CA) as a combined preparation for simultaneous, separate or sequential use in the treatment of solid tumors.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of potentiating the chemotherapeutic regimen comprising administration of a BM in addition to a CA.

ACTIVITY - Cytostatic.

The effects of a BM and a CA were evaluated in a clinical study. The CAs used were paclitaxel and carboplatin, and the BM was (IIa). Cancer patients with late-stage disease were given (IIa) 7 days before the paclitaxel (175-200 mg/m²) and carboplatin (dose was such that area under curve is 6 mg/ml multiply minute). Patients received a second dose of CA 21 days later, and then on days 22 and 29 (IIa) was administered. Three patients received a dosage of (IIa) of 0.1 micro g/kg, 2 patients experienced complete reduction of the tumor, and 1 experienced partial reduction of the tumor. Six patients received a dosage of (IIa) of 0.2 mu g/kg, 1 experienced partial reduction of the tumor, 2 experienced stabilization of the tumor, and 1 experienced tumor progression. Four patients received a dosage of (IIa) of 0.266 micro g/kg, 1 patient experienced complete reduction of the tumor, 1 experienced partial reduction of the tumor, 1 experienced stabilization of the tumor, and 1 experienced tumor progression. Three patients received a dosage of (IIa) of 0.4 micro g/kg, 1 patient experienced complete reduction of the tumor, 1 experienced stabilization of the tumor, and 1 experienced tumor progression. Of all of the patients tested, 69 % experienced complete or partial tumor reduction, or tumor stabilization.

MECHANISM OF ACTION - Cytokine inducer; Microtubular agent; Macrophage activating agent.

USE - (I) is used for the treatment of solid tumors (claimed), especially non-small cell lung carcinoma, glioma, ovarian cancer, breast cancer, prostate cancer, cancers of the head and neck, kidney, pancreas, liver and colon and soft tissue sarcoma.

ADVANTAGE - The two components can be administered simultaneously, or in a staggered regimen. The BM potentiates the

09/659643

effect of the CA.
Dwg.0/0

L20 FILE 'REGISTRY' ENTERED AT 15:25:25 ON 18 NOV 2002
218362 SEA FILE=REGISTRY ABB=ON PLU=ON ?ALANINE?/CNS
L35 6 SEA FILE=REGISTRY ABB=ON PLU=ON ?"CARBOXY-N2-((2-CARBOX
Y")?/CNS
L36 5 SEA FILE=REGISTRY ABB=ON PLU=ON L35(S)L20
L37 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L36

(FILE 'HCAPLUS' ENTERED AT 15:36:35 ON 18 NOV 2002)
L37 1 S L36

=> s 137 not l10
L38 0 L37 NOT L10

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO, CANCERLIT' ENTERED AT 15:38:16 ON 18 NOV 2002)
L39 0 S L37

FILE 'HOME' ENTERED AT 15:38:38 ON 18 NOV 2002